BridGene Biosciences
A biotech company developing innovative small molecules that drug traditionally undruggable targets.
By using its proprietary chemoproteomic platform, IMTAC, BridGene is able to screen small molecules against all proteins in live cells to discover drug candidates for high value and previously undruggable targets. For this purpose, BridGene takes advantage of its proprietary, diverse covalent library of tagged, drug-like small molecules.
BridGene is advancing a pipeline of first-in-class drugs for targets in multiple disease areas.
Latest BridGene Biosciences News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze